When quantifying the expression of immune checkpoint CD8, PD-L1, and the level of abnormal fat metabolism in lung cancer tissues received immunotherapy, we further proved that immunoactivation markers CD8 and PD-L1 were significantly higher in the R group. This evidence concerns the gene CD8A and lung cancer.